Search
for
Sort by
Research 61–90 of 1000+
- Finasteride in the treatment of alopecia
- Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches
- A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
- Current Pharmacological Treatment for Male LUTS due to BPH: Dutasteride or Finasteride?
- Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasteride
- LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
- Recent advances in nanocarrier-loaded gels: Which drug delivery technologies against which diseases?
- Medicinal Chemistry of Drugs with <i>N</i>-Oxide Functionalities
- Progesterone, neurosteroids, and the hormonal basis of catamenial epilepsy
- Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment
- An Insight on Ellagic Acid Formulations for the Management of Skin Diseases
- Deciphering of Anti-Alopecia Activity of Polyphenol from Beta vulgaris Root against 5α-reductase: Molecular Insight
- Discovery and Optimization of Novel Pyridines as Highly Potent and Selective Glycogen Synthase Kinase 3 Inhibitors
- Exploring murE protein inhibitors of Tropheryma whipplei through pharmacoinformatic approaches incorporating solubility-enhancing formulation insights
- Progestogens in menopausal hormone therapy
- Comprehensive Evaluation of <i>Tectona grandis</i> L.f.: Integrated <i>In Vitro</i> and <i>In Silico</i> Analysis of Steroid 5α-Reductase Inhibition and Anti-Inflammatory Properties
- 5 Alpha Reductase Inhibitors
- Teriflunomide efficacy, safety and tolerability in patients with relapsing forms of multiple sclerosis
- A Simple Decision Tree Suited for Identification of Early Oral Drug Candidates With Likely Pharmacokinetic Nonlinearity by Intestinal CYP3A Saturation
- A regulatory perspective on pharmacokinetic/pharmacodynamic modelling
- Monoclonal Antibody Against Prolactin Receptor: A Randomized Placebo-Controlled Study Evaluating Safety, Tolerability, and Pharmacokinetics of Repeated Subcutaneous Administrations in Postmenopausal Women
- Single and repeated dose of finasteride topical solution in subjects with androgenetic alopecia: A pharmacokinetic and pharmacodynamic study
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Pharmacokinetic Interaction of Finasteride With Tamsulosin Hydrochloride: An Open-label, Randomized, 3-period Crossover Study in Healthy Chinese Male Volunteers
- Unlocking Dithranol’s Potential: Advanced Drug Delivery Systems for Improved Pharmacokinetics
- Pharmacokinetic and Therapeutic Dose Comparison of Diane-35 and IVF-C Inj 5000 IU in Common Quail
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- HPLC Profiling and Insilco studies of Chochurus olitoris (Jute) Leave Fractions against Steroid 5α-Reductase 2 (SRD5α2)
- Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
- The safety profiles of avacopan on microscopic polyangiitis and granulomatosis with polyangiitis: a real-world pharmacovigilance analysis